Company intelligence / Profile preview

Immunolight

Durham, North Carolina, United Statesimmunolight.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Received FDA clearance to enter phase 1 study in patients with breast, melanoma, sarcoma and head and neck cancers in August 2021. The technology converts low dose X-ray into UV light inside solid tumors to activate psoralen, which kills cancer cells.

Therapeutic areas: Oncology
Modalities: Energy conversion technologyPsoralen activation
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

psoralen

Phase 1

Indications: Breast cancer, Melanoma, Sarcoma, Head and neck cancer, Solid tumors

Partnerships

Duke University

Beyond the preview

Go deeper on Immunolight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunolight.

Explore the full profile